Price
Target price
€17.92
€17.92
-1.180%
-0.215
-1.180%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Syndax Pharmaceuticals Inc Stock
A loss of -1.180% shows a downward development for Syndax Pharmaceuticals Inc.
So far the community has only identified positive things for Syndax Pharmaceuticals Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Syndax Pharmaceuticals Inc in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Syndax Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | -1.180% | -11.136% | -17.060% | 53.120% | 0.084% | -6.693% | 35.720% |
| Rockwell Medical Inc. | 2.720% | -2.055% | -4.027% | -29.557% | 5.691% | -66.975% | -91.824% |
| Pacira Pharmaceuticals | 0.000% | 2.857% | 9.091% | -1.818% | 0.000% | -45.729% | -58.857% |
| Twist Bioscience Corp | -1.270% | -5.360% | 30.558% | 44.658% | 81.329% | 345.719% | -56.690% |
News
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
DAFNA Capital Management reported selling 222,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.89 million based on
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $8.18
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
On February 17, 2026, Sphera Funds Management Ltd. disclosed a purchase of 374,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $6.54 million trade based on quarterly average